Author:
Chereddy Kiran Kumar,Ganipineni Lakshmi Pallavi
Reference83 articles.
1. Aijaz A, Li M, Smith D, Khong D, LeBlon C, Fenton OS et al (2018) Biomanufacturing for clinically advanced cell therapies. Nat Biomed Eng 2(6):362–376
2. Alapati D, Morrisey EE (2017) Gene editing and genetic lung disease. Basic research meets therapeutic application. Am J Respir Cell Mol Biol 56(3):283–290
3. Al-Rubaie A, Wise AF, Sozo F, De Matteo R, Samuel CS, Harding R, Ricardo SD (2018) The therapeutic effect of mesenchymal stem cells on pulmonary myeloid cells following neonatal hyperoxic lung injury in mice. Respir Res 19(1):114. https://doi.org/10.1186/s12931-018-0816-x
4. Alton EWFW, Armstrong DK, Ashby D, Bayfield KJ, Bilton D, Bloomfield EV, et al.(2016) A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis
5. Alton EWFW, Beekman JM, Boyd AC, Brand J, Carlon MS, Connolly MM et al (2017) Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis. Thorax 72(2):137. https://doi.org/10.1136/thoraxjnl-2016-208406